

Summary of Product Characteristics

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1 NAME OF THE MEDICINAL PRODUCT

TOPAMAX 25 mg Film-coated Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 25 mg of topiramate.

Excipient with known effect: lactose monohydrate

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Film-coated tablet.

Product imported from *Greece, Belgium and Croatia*

White, round tablets marked 'TOP' on one side and '25' on the other.

4 CLINICAL PARTICULARS

As per PA22612/013/001

5 PHARMACOLOGICAL PROPERTIES

As per PA22612/013/001

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Core tablet:

Lactose Monohydrate
Pregelatinized Maize Starch
Microcrystalline Cellulose
Sodium Starch Glycolate (Type A)
Magnesium Stearate

Film-coating:

OPADRY White¹
Carnauba Wax

¹OPADRY White contains:

Hypromellose
Macrogol
Polysorbate 80
Titanium dioxide (E171)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

The shelf life expiry date of this product is the date shown on the container and outer carton of the product as marketed in the country of origin.

6.4 Special precautions for storage

Do not store above 25°C.

Blister packs: Store the tablets in the original package to protect the tablets from moisture.

Bottles: Store in the original package and keep the bottle tightly closed to protect the tablets from moisture.

6.5 Nature and contents of container

Opaque plastic bottle with tamper-evident closure containing 60 tablets. In each bottle there is a desiccant canister which should not be swallowed.

Blister pack of an aluminium/aluminium foil in strips. Pack sizes of 60 tablets. Individual (alu/alu) blister strips are packed inside a folding box.

6.6 Special precautions for disposal

No special requirements.

7 PARALLEL PRODUCT AUTHORISATION HOLDER

IMED Healthcare Ltd.,
Unit 625 Kilshane Avenue
Northwest Business Park
Ballycoolin
Dublin 15
Ireland

8 PARALLEL PRODUCT AUTHORISATION NUMBER

PPA1463/136/002

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 16th April 2021

10 DATE OF REVISION OF THE TEXT

November 2025